Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
1. BMO Capital Markets initiates coverage on Dyne with an Outperform rating. 2. Dyne targets therapies for genetically driven neuromuscular diseases through its FORCE platform. 3. Phase 1/2 trial data for DM1 shows promise in Dyne’s lead candidate DYNE-101. 4. Analyst predicts $50 price target and $4.3 billion sales by 2035 for Dyne. 5. FDA's decision on DM1 pathway remains a key factor for Dyne's market entry.